Quinapril

An ACE inhibitor blood pressure medicine, FDA-approved for hypertension and, as add-on therapy, heart failure.

psilodex.org/m/quinapril · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~2 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado Condition rules (3)

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Quinapril”, v2026.10.05. psilodex.org/m/quinapril

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

Generic only in US

FDA-approved for

High blood pressure (hypertension)
Heart failure (add-on to diuretics and/or digitalis)

Sources [1]

Other safety

Boxed warning: drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

It lowers blood pressure and may lessen psilocybin's temporary blood pressure rise (not studied with psilocybin).

Detail Quinapril is an ACE inhibitor that lowers blood pressure. It may lessen psilocybin's transient blood pressure rise (no psilocybin data). It is not known to affect how the body clears psilocin (psilocybin's active form).

Human data with psilocybin: No psilocybin data; based on how it works
Half-life: ~2 h (quinaprilat) (FDA label, checked 2026-10-04) Active metabolite quinaprilat; prolonged terminal phase ~25 h; effective accumulation half-life ~3 h on multiple dosing.

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Lowers blood pressure or causes orthostasis: Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Hypertension (provision applies if uncontrolled)
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees
Heart failure or past heart attack
- CO 2.5(A)(2) · Clinical Facilitator licensees
- CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
- CO 6.16(F)(1) · All licensees

05 Sources

Quinapril Tablets, USP (Aurobindo) · FDA label (DailyMed) — Lowers blood pressure or causes orthostasis: Warnings: Hypotension "Excessive hypotension is rare in patients with uncomplicated hypertension treated with quinapril hydrochloride alone." | Clinical Pharmacology "Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose, and has an elimination half-life in plasma of approximately 2 hours and a prolonged terminal phase with a half-life of 25 hours." | Boxed Warning "Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus." | revised 2024-05

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →